Biomarkers of neurodegenerative disorders are needed to assist in diagnosis, to monitor disease progression and therapeutic interventions, and to provide insight into disease mechanisms. One route to identify such biomarkers is by proteomic and peptidomic analysis of cerebrospinal fluid (CSF).
Introduction
Analysis of cerebrospinal fluid (CSF) is valuable to study neurodegenerative disorders (1) .
Research on diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD) would benefit greatly from new biomarkers that can aid in diagnosis, be used for monitoring disease progression, and provide insight into the disease mechanisms. As new disease-modifying therapies are being developed, for example against AD (2), there will be an increased need for biomarkers that enable earlier and more accurate diagnosis, as well as to provide means to monitor disease progression and response to treatment.
Produced as an ultra-filtrate of blood in the ventricles and around the blood vessels of the central nervous system (CNS), CSF circulates around the brain and the spinal cord and is drained into the blood, with a turnover time of approximately 8 h (3) . A multitude of molecules shed by cells in the brain are present in CSF, and thus, many processes in the CNS are dynamically reflected in the molecular composition of the CSF. Approximately 20% of the protein content is derived from the CNS through the interstitial fluid and the remainder can be traced to plasma constituents passing the blood-brain barrier (4) (5) (6) (7) (8) (9) . Shotgun proteomic studies of CSF have led to the identification of biomarker candidates of several neurodegenerative disorders, including AD, PD, and multiple sclerosis (10) .
Studies by our group and others have revealed that CSF, besides proteins, contains many endogenous peptides (11) (12) (13) (14) (15) (16) . Their concentration being dependent on a variety of processes, such as enzymatic protein processing, secretion, and aggregation, these peptides may convey valuable biomarker information. Such information may obviously be lost when following the currently standard analytical strategy in proteomics of digesting the sample proteins with trypsin and basing protein quantification on measurement of tryptic peptides.
From an analytical point of view, endogenous peptides are attractive: circumventing proteolytic digestion eliminates a source of analytical variability and reduces cost and sample preparation time, which are important aspects for establishing assays for clinical research and routine settings. Furthermore, endogenous peptides can be readily isolated by molecularweight ultrafiltration from the high-abundant proteins that make up the bulk of the CSF protein contents, such as albumin and immunoglobulins, allowing a larger volume of CSF peptide extract to be used for LC-MS analysis and thereby enabling detection of lowerabundant peptides.
In a pilot study we identified quantitative differences in endogenous peptides in AD patients compared to controls (17) , suggesting their potential as biomarkers. In a recent study, we used endopeptidomics to detect changes in the abundance of endogenous CSF peptides in healthy individuals following treatment with the -secreatase inhibitor semagacestat demonstrating target engagement (18) .
In order to further investigate the potential of endogenous peptides in CSF as biomarkers, the aim of the current study was to expand the known CSF peptidome to include also more lowabundant peptides. Our approach was to implement a step of peptide pre-fractionation to allow increased CSF volume to be used for LC-MS analysis, and employing software that employs different algorithms for peptide identification and scoring of spectrum matches.
Experimental Procedures

Participants and sampling of cerebrospinal fluid
Cerebrospinal fluid was sampled from one patient diagnosed with hydrocephalus undergoing evaluation at Lund University Hospital, Lund, Sweden; as well as from CSF pooled from five individuals undergoing evaluation at the Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden. Sampling was performed by lumbar puncture in accordance with a standardised protocol previously developed on site. Non-soluble material, cells and cell debris in the CSF were removed by centrifugation at 2000 x g and +4 °C for 10 min. Surplus CSF from patients undergoing clinical evaluation was used for this project after de-identification, as approved by the regional ethics committee at the University of Gothenburg. 
Materials
CSF sample preparation -endogenous peptides
CSF peptide extracts were prepared according to a previously described protocol (19) , modified to accommodate a larger sample volume. Briefly, 1.5 ml aliquots of CSF were thawed at room temperature (RT), vortexed gently, and transferred to 15 ml Falcon tubes. The filters were conditioned by adding a solution of 100 mM TEAB, 3 M Gua-HCl (5 ml) and centrifuging at 2,500 x g for 20 min at RT, discarding the flow-through. The samples were then loaded and centrifuged (2,500 x g for 45 min, RT). To improve recovery, 50 mM AmBic (3 ml) were loaded, spun through (RT, 2,500 x g for 20 min) and pooled with the filtrate.
The sample was acidified (final pH ≈ 3) by titration with 0.1% TFA and subsequently desalted by SPE (SEP-Pak C 18 ), operated using a vacuum chamber. The cartridge was conditioned with 2 x 1 ml 84% AcN, 0.1% TFA, and equilibrated by 2 x 1 ml 0.1% TFA, after which the sample was loaded, washed with 2 x 1 ml 0.1% TFA and subsequently eluted with 1 ml 84% AcN, 0.1% TFA. Finally the eluate solvents were evaporated in a vacuum concentrator and at -80 °C.
CSF sample preparation -tryptic peptides
For comparing the identification rates of endogenous and tryptic peptides, an aliquot of the CSF sample from the hydrocephalus patient was digested with trypsin. CSF (100 µl) was thawed at RT, vortexed gently and transferred to a 1.5 ml Eppendorf tube. Aliquots of 1 M TEAB (16.7 µl) and 3.3% Na-DOC (50 µl) were added and the sample was vortexed.
Reduction of protein disulphides was performed by adding an aliquot of 200 mM TCEP, 300 mM TEAB (4 µl) followed by 1 h incubation at +55 °C under gentle agitation. Cysteines were alkylated by addition of 400 mM IAA (4 µl) followed by 30 min incubation at RT in darkness. Trypsin (Promega, 20 µg) was dissolved in 50 mM acetic acid (100 µl) and preincubated for 15 min at 37 °C. A 25 µl aliquot of the solution was transferred to the sample, which was incubated 12 h at 37 °C. The sample was subsequently desalted, concentrated, and stored as described above.
Alkaline Reverse-Phase HPLC Separation and Fraction Concatenation
HpH-RPLC fractionation was performed according to the method of Bath et al (20) with minor method alterations, using a Ultimate 3000 HPLC system (Thermo) equipped with an integrated fraction collector adapted for 96-well deep well plates. Endogenous peptide extracts (from 1.5 ml CSF) were dissolved in 2.5 mM NH 3 (aq) and 2% AcN (15 µl), and separated over an XBridge Peptide BEH C 18 Column, 130 Å . The mobile phases consisted of (A) pure water; (B) 84% AcN; and (C) 25 mM NH 3 (aq). Buffer C was made fresh at the start of each trial and kept on ice to minimize NH 3 (aq) decomposition/evaporation. The LC was operated at a constant flow of 100 µl/min with a constant concentration of 10% Buffer C, and using the following gradient: t (min)=0, %B=2%; t=4, B=2%; t=50, B=90%; t=66, B=90%; t=67, B=2%; t=76, B=2%. Fraction collection was started at t=4 min, collecting 72 oneminute fractions in a cycling pattern over 24 wells in a 96-well deep-well plate, resulting in 3 concatenated fractions per well. The fractions were further concatenated by combining the contents of well 1 and 13, 2 and 14, 3 and 15 etc., resulting in 12 samples, each containing six of the original fractions. The fractions were subsequently split in two aliquots, vacuum concentrated and stored at -80 °C until LC-MS analysis.
LC-MS
Chromatography was performed on an Ultimate 3000 RSLC nano system (Thermo) in trap column configuration (trap column: Acclaim® PepMap 100 (Thermo), 75 µm x 2 cm, C 18 , 100 Å pore size, 3 µm particle size; separation column: Acclaim® PepMap C18, 75 µm x 500 mm, 100Å pore size, 2 µm particle size). The mobile phases were (A) 0.1% FA and (B) 84% AcN, 0.1% FA. Sample aliquots corresponding to 750 µl CSF were dissolved in 0.05% TFA, 2% AcN (6 µl) (loading buffer). 5 µl were loaded at 5 µl/min using 0.05% TFA, 2% AcN.
The following gradient was used: t (min) =0, B=2%; t=10, B=2%; t=11, B=7%; t=100, B=26%; t=170, B=45%; t=175, B=80%; t=181, B=2%; t=210, B=2%. The LC was connected to an Orbitrap Fusion™ Tribrid™ mass spectrometer (Thermo) via a FlexiSpray nano-ESI interface (Thermo). Full scan spectra were recorded in MS mode at a resolution setting of 120,000 (2.0e5 AGC target) over the m/z range 350-1400. The mass spectrometer was operated in the data-dependent acquisition mode, recording MS/MS spectra from the top ten most intense peaks with m/z > 150 and within the intensity range 1.0e4-1.0e5 were selected for fragment ion analysis. Precursor ions were isolated using a quadrupole isolation window 
Results and Discussion
To increase the number of identified endogenous peptides in CSF we supplemented a previously developed protocol (19, 24) , based on molecular weight ultrafiltration, with an additional peptide fractionation step employing high-pH reversed-phase chromatography according to the method described by Batth and colleagues (20) . Besides reducing sample complexity, pre-fractionation enabled us to use a fivefold larger volume of CSF for nano-LC-MS analysis compared to our previous studies, permitting the detection of lower-abundant peptides. We also evaluated software programs that use different strategies for peptide identification and validation of PSMs. Identified peptides were evaluated based on previously reported association to neurodegenerative disorders and peptides of particular interest (i.e., derived known or potential biomarkers) were examined further.
Peptide identification
The identification success rate is generally lower for endogenous peptides than for tryptic
peptides. An LC-MS data set of tryptic peptides from CSF, consisting of 427,613 MS/MS spectra, resulted in 36,886 confident (FDR<1%) PSMs, corresponding to 8.6% identified spectra, while a set of endogenous CSF peptides, consisting of 269,945 MS/MS spectra, yielded 3,094 accepted PSMs, i.e., only 1.1% identified spectra. A reason for the lower identification rate for endogenous peptides may be that they differ in composition compared to tryptic peptides: for example, they are on average longer, and contain lysine and arginine residues internally but not necessarily at the C-terminus. Thus PSM scoring algorithms optimized for tryptic peptides may not be optimal for endogenous peptides. To test this hypothesis, we searched LC-MS data from one sample (12 HpH-RPLC fractions) with the software programs Mascot (25, 26) and SequestHT (27, 28) , which are based on fragment ion fingerprinting (26, 29) , for both programs using either the default scoring algorithm or the Percolator algorithm (21, 30) . While both algorithms use the target/decoy approach to assess the correctness of PSMs, Percolator employs machine learning to improve the base scoring algorithm based on a subset of highly confident PSMs in an iterative process. Thereby, the algorithm can adapt to the general fragmentation characteristics of peptides in the given sample and mass spectrometric experiment. Mascot identified 1,276 endogenous peptides using the default algorithm, and 8,679 peptides using Percolator, corresponding to over a 6fold increase ( Figure 1A) . Sequest HT identified 1,694 endogenous peptides using its default scoring algorithm, and improved more than four-fold, to 7,288 peptides when instead applying Percolator ( Figure 1B) . For tryptic peptides the differences between Percolator and the default scoring algorithms were smaller: Mascot identified 5,824 peptides using the default algorithm and 7,926 peptides using Percolator, corresponding to an increase of 36% ( Figure 1C) , and SequestHT 7,028 peptides using the default algorithm and 7,917 using
Percolator, corresponding to an increase of 12% ( Figure 1D) .
Another difference regarding identification of endogenous peptides compared to tryptic peptides is that no enzymatic cleavage can be specified in the database search. Thereby, the number of peptide sequences to evaluate increases by a factor of 100-1,000, increasing the occurrence of incorrect PSMs. De novo sequencing is an alternative to fragment ion fingerprinting for peptide identification, in which partial peptide sequences are extracted by using intrinsic m/z information in MS/MS spectra (31) . Because this approach does not rely on knowledge of the amino acids at the peptide termini, we hypothesized that it may be more successful for identification of endogenous peptides. To test this hypothesis, we searched the LC-MS data from the previous section using PEAKS Studio (32) , which identifies peptides by de novo sequencing followed by a tag search (33, 34) , and uses a PSM validator which combines machine learning and target decoy functions, some of which are also featured in Percolator, in a decoy fusion PSM validator (35) . PEAKS identified 10,967 peptides (1% FDR), i.e., nearly 2,500 peptides more than Mascot and more than 3,000 peptides more than SequestHT (Figure 2 ).
The identification overlap between PEAKS and the data-dependent search engines was quite small. Compared to 70% peptide identification conformity between Mascot and Sequest HT, the identification overlap between PEAKS and either of the other two search engines was less than 20%, and the total overlap between all three was less than 15% ( Figure 2 ). The number of peptides identified with the different programs and scoring algorithms are listed in Table 1 .
The small overlap between the fingerprinting and de novo based methods raises the question of whether the identifications are correct or not. While correctness cannot be directly tested in this data set, for the subset of MS/MS spectra with assigned PSMs in at least two programs, the percent discrepant PSM assignments between the programs could reveal if the actual FDR of either of the programs is higher than the target value. The discrepancies between the programs were below 2% in all cases, thus not indicating erroneous FDR (Table 2 ).
In conclusion, for identification of endogenous peptides by fragment ion fingerprinting, the optimal scoring algorithm differs from that of tryptic peptides, and a significant improvement can be achieved by using an adaptive scoring approach such as Percolator. Further, our results
show that peptide identification based on de novo sequencing and fragment ion fingerprinting are complementary and should be used in combination for increased number of identified peptides.
Evaluation of biomarker candidates
Combining the results from the two CSF samples searched by three search engines resulted in a total of 18,031 unique endogenous peptides (FDR=1%), derived from 1,918 proteins. The set of proteins identified in our study was compared to CSF biomarkers and biomarker candidates presented in four recent review articles (3, 10, 36, 37) (see Table 3 ).
Microtubule-Associated Protein Tau
Among the identified endogenous peptides of particular interest were five derived from microtubule-associated protein tau (Table 4 , Figure 3 ). In humans the primary role of tau is to stabilise neuronal microtubules, which are vital to axonal transport (38, 39) . Intraneuronal aggregation of tau in the brain is involved in several neurodegenerative diseases, which are collectively referred to as tauopathies (40, 41) . A specific pathophysiological trait of AD is phosphorylation of one or several tau-motifs (42) (43) (44) , resulting in so-called hyperphosphorylated tau (p-tau). Hyperphosphorylation causes tau to dissociate from the microtubule-network, leading to its breakdown, and eventually results in cell-death (44, 45) , resulting in increased CSF tau level (46) (47) (48) . Together with the amyloid beta 1-42 peptide (Aβ 1-42 ), total tau (t-tau) and p-tau can be used to diagnose AD with high sensitivity and specificity (1, 37, 48, 49) .
A study in which fractionated CSF proteins were analysed by Western blot demonstrated the existence of a multitude of tau protein fragments spanning a wide molecular weight range (47) . The data indicated differences in the abundance of several fragments between AD patients and controls, suggesting that it may be important to study the disease association of specific tau fragments or endogenous tau peptides. Our study is the first to report endogenous Table s1 ). A majority of the truncated, endogenous Aβ peptide forms we report on here have been previously identified using a combination of immunoprecipitation (IP) and MS (51, 52) . However; we identified a number of truncated segments not previously reported, in some cases likely because their sequences were outside the epitopes of the antibodies (12EF325, 6E10, and 4G8) used. A further three peptides (-10 to 9, -15 to 9 and -8 to 2) were not completely located within the Aβ sequence.
Endogenous peptides located within the Aβ 1-42 sequence are of particular interest when studying enzymatic processing of the Aβ/APP, e.g., to confirm target engagement of betasecretase inhibitor treatment (53)
Apolipoprotein E
109 endogenous peptides derived from apoE were identified ( Supplemental Table s1 ). Apolipoprotein E (apoE) is a glycoprotein which known functions involve CNS lipid transport and peripheral circulation (54) . It is also believed to be a "progenitor" for bioactive polypeptides resulting from proteolytic cleavage of the protein (55) (56) (57) . ApoE is known to be involved in AD and other neurodegenerative diseases (58) (59) (60) , and there is evidence suggesting the protein affects AD through interaction with Aâ 1-42 (61, 62) , but the exact mechanism is still not fully understood. We identified 109 endogenous apoE peptides covering >70% of the protein-sequence. Among the identified peptides were 6 spanning AA-130, and 3 spanning AA-176 allowing for separate quantification of endogenous peptides produced from the different genetic variants in future studies.
Conclusions
The described sample preparation, peptide fractionation, and peptide identification using different search engines significantly expanded the known CSF peptidome. The large number of endogenous CSF peptides identified, many of which have been reported to be associated with neurodegenerative diseases and comprising also peptides from low-abundant proteins, strongly suggests that this class of molecules is a promising source of biomarkers to explore in clinical studies. 
